Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The GLP2 receptor (GLP2R) is a G protein-coupled receptor superfamily member closely related to the glucagon receptor ans GLP1 receptor. Additionally we are shipping Glucagon-Like Peptide 2 Receptor Proteins (10) and Glucagon-Like Peptide 2 Receptor Kits (3) and many more products for this protein.
Showing 10 out of 94 products:
Human Monoclonal GLP2R Primary Antibody for ELISA, WB - ABIN395085
Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. in Diabetes Care 2010
Show all 5 references for ABIN395085
Human Polyclonal GLP2R Primary Antibody for DB, EIA - ABIN493012
Velázquez, Ruiz-Albusac, Blázquez: Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes. in European journal of biochemistry / FEBS 2003
Show all 3 references for ABIN493012
Human Polyclonal GLP2R Primary Antibody for EIA, WB - ABIN952529
Pinheiro, Bulik, Thornton, Sullivan, Root, Bloss, Berrettini, Schork, Kaye, Bergen, Magistretti, Brandt, Crawford, Crow, Fichter, Goldman, Halmi, Johnson, Kaplan, Keel, Klump, La Via, Mitchell, Strober, Rotondo, Treasure, Woodside: Association study of 182 candidate genes in anorexia nervosa. in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2010
Show all 2 references for ABIN952529
Human Polyclonal GLP2R Primary Antibody for WB - ABIN2787698
Sams, Hastrup, Andersen, Thim: Naturally occurring glucagon-like peptide-2 (GLP-2) receptors in human intestinal cell lines. in European journal of pharmacology 2006
Show all 2 references for ABIN2787698
Human Polyclonal GLP2R Primary Antibody for IF, IHC (p) - ABIN122262
Baldassano, Liu, Qu, Mulè, Wood: Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. in American journal of physiology. Gastrointestinal and liver physiology 2010
The GLP-1 (show GCG Antibodies) secretion after 75 g OGTT was impaired in newly diagnosed T2DM patients, inversely proportional to insulin (show INS Antibodies) resistance and hyperglycemia, and positively correlated with beta-cell function and insulin (show INS Antibodies) sensitivity.
GLP-1 (show GCG Antibodies) secretion increased in response to inflammatory stimuli in humans, which was associated to parameters of glucose metabolism and best predicted by IL6 (show IL6 Antibodies).
Among young and healthy adults, GLP-1 (show GCG Antibodies) levels are strongly and independently related to body fat mass especially in men, but not body mass index or waist circumference.
Glucagon (show GCG Antibodies) circulates in patients without a pancreas and glucose stimulation of the gastrointestinal tract elicits significant hyperglucagonemia in these patients.
There is minor contribution of endogenous GLP-1 and GLP-2 to postprandial lipemia in obese men.
Data suggest that endocrine responses differ between jejunal and gastric enteral feeding, with higher peak plasma CCK (cholecystokinin), PYY (peptide YY), and GLP-1/2 (glucagon-like peptides 1/2) concentrations being attained after jejunal feeding.
Data suggest that capsaicin, an appetite suppressant dietary supplement (here, administered via intraduodenal infusion), does not act via alteration of secretion of satiety hormones GLP-1 (GLP-1) and PYY (peptide YY).
Data show that NCI-H716 cells were immunostained for tumor necrosis factor (show TNF Antibodies) receptor TNFR1 (show TNFRSF1A Antibodies), and TNFalpha (show TNF Antibodies) treatment enhances glucagon-like peptide-1 (GLP-1 (show GCG Antibodies)) secretion.
active GLP-1 (show GCG Antibodies) produced in the islet stimulates cholecystokinin (show CCK Antibodies) production and secretion in a paracrine manner via cyclic AMP (show APRT Antibodies) and CREB (show CREB1 Antibodies).
Data suggest that secretion of insulin (show INS Antibodies) and glucagon (show GCG Antibodies) is up-regulated in subjects with type 2 diabetes with dyssomnia as compared to subjects with type 2 diabetes without dyssomnia; those with dyssomnia exhibit prehypertension and insulin (show INS Antibodies) resistance.
Results suggest that GLP-2 (show GCG Antibodies) protected and improved memory function in LPS (show TLR4 Antibodies)-treated mice, and also had anxiolytic effects due to changes in the 5-HT (show DDC Antibodies) system.
Report gastrointestinal GLP-2 receptor andl limited utility of GLP-2 in the management of inflammatory intestinal disorders.
GLP-2 (show GCG Antibodies) plays a key physiological role in the control of hepatic glucose production through activating PI3K-dependent modulation of membrane excitability and nuclear transcription of POMC (show POMC Antibodies) neurons in the brain.
Data suggest a role for endogenous GLP2 (glucagon-like peptide-2 (show GCG Antibodies)) and GLP2R in adaptation of mucosa of duodenum and jejunum to high-fat diet; results suggest dysregulation of GLP2/GLP2R signaling in obesity due to prolonged high-fat diet.
The data indicated that CNS GLP-2 receptor plays a physiological role in the control of feeding behavior and gastric emptying and that this is mediated probably through the melanocortin system.
Data suggest that the Vip (show Vip Antibodies) gene is not required for induction of a gene expression program linked to small bowel growth after enhancement of GLP-2 receptor signaling.
Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis
Data show that the GLP-2R is expressed by inhibitory and excitatory neurons, and inhibits the muscle contractility likely by decreasing cholinergic neurotransmission and increasing nitric oxide production.
GLP-2R is not critical for the stimulation/suppression of glucagon (show GCG Antibodies) secretion or glucose homeostasis in normal or lean diabetic mice. In obese mice GLP-2R signaling mediates the normal islet adaptive response required to maintain glucose homeostasis.
Glucagon-like peptide-2 (show GCG Antibodies) potentiates L-type voltage-gated Ca(2 (show CA2 Antibodies)+) channels activity through activating cAMP-dependent protein kinase A signaling, partially stimulating glucose uptake by primary cultured hippocampal neurons.
data demonstrate that cattle express proglucagon (show GCG Antibodies) and glucagon-like peptide 2 receptor mRNA primarily in small intestinal and colon tissues
The GLP2 receptor (GLP2R) is a G protein-coupled receptor superfamily member closely related to the glucagon receptor ans GLP1 receptor. Glucagon-like peptide-2 (GLP2) is a 33-amino acid proglucagon-derived peptide produced by intestinal enteroendocrine cells. Like glucagon-like peptide-1 (GLP1) and glucagon itself, it is derived from the proglucagon peptide encoded by the GCG gene. GLP2 stimulates intestinal growth and upregulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. Moreover, GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut and closely related to the glucagon receptor (GCGR) and the receptor for GLP1 (GLP1R).
glucagon-like peptide 2 receptor
, glicentin-related polypeptide
, glucagon-like peptide 1
, glucagon-like peptide 2
, GLP-2 receptor
, G protein-coupled receptor GLP2R
, glucagon-like peptide-2 receptor